Acute Kidney Injury — Part 3: Conservative Management of AKI Complications

1. Fluid Management in AKI

1.1 Assessment of Volume Status

Accurate assessment of volume status is fundamental to AKI management. Both hypovolemia and hypervolemia are harmful to the injured kidney. The challenge in critically ill patients is that traditional clinical signs (JVP, peripheral edema, lung crackles) have poor sensitivity and specificity for intravascular volume status.^{1 2}

Integrated Volume Assessment

1.2 Fluid Responsiveness vs. Fluid Tolerance

A paradigm shift in ICU fluid management recognizes that being “fluid responsive” does not necessarily mean that fluids should be given. The decision to administer fluids requires answering two questions:²

1. Is the patient fluid responsive? (Will a fluid bolus increase cardiac output?)
2. Is the patient fluid tolerant? (Can the patient accommodate the additional volume without harm — i.e., without worsening pulmonary edema, intra-abdominal pressure, or venous congestion?)

Key Concept: In AKI patients with fluid overload, the goal shifts from resuscitation to de-resuscitation — active fluid removal through diuretics or ultrafiltration to relieve venous congestion and reduce interstitial edema.

1.3 Fluid Overload Recognition and Significance

Fluid overload is defined as a cumulative positive fluid balance exceeding 10% of baseline body weight and is independently associated with adverse outcomes in AKI:^{3 4}

• Mortality: Fluid overload is associated with a 2-3-fold increase in mortality in AKI patients, independent of AKI severity
• AKI progression: Fluid overload worsens AKI through renal venous congestion, increased renal interstitial pressure, and renal compartment syndrome
• Respiratory failure: Pulmonary edema impairs gas exchange and may necessitate or prolong mechanical ventilation
• Impaired wound healing, bowel edema, intra-abdominal hypertension

Fluid overload severity grading:

2. Electrolyte Management

2.1 Hyperkalemia — Emergency Management

Hyperkalemia is the most immediately life-threatening electrolyte derangement in AKI. Serum potassium > 6.0 mEq/L or any level with ECG changes constitutes a medical emergency requiring immediate treatment.^{1 5}

ECG Changes of Hyperkalemia (Progressive)

Critical Warning: ECG changes do not reliably correlate with specific potassium levels in individual patients. Any patient with potassium > 6.0 mEq/L should be placed on continuous cardiac monitoring and have an ECG performed immediately. The absence of ECG changes does not exclude lethal hyperkalemia.

Hyperkalemia Emergency Treatment Algorithm

Step 1: Cardiac Membrane Stabilization (immediate — within 1-3 minutes)

Note: Calcium should be given first, before any potassium-lowering therapy, if ECG changes are present. It is a temporizing measure only.

Step 2: Intracellular Potassium Shift (onset 15-30 minutes)

Step 3: Potassium Removal from the Body

2.2 Metabolic Acidosis

AKI results in metabolic acidosis through two primary mechanisms: (1) reduced renal excretion of hydrogen ions and (2) reduced renal regeneration of bicarbonate. Additionally, accumulation of uremic organic acids contributes to the anion gap.^{1 6}

Assessment:

Management:

• Mild acidosis (pH 7.20-7.35): Generally well tolerated; optimize renal function; correct underlying cause
• Moderate acidosis (pH 7.10-7.20): Consider sodium bicarbonate infusion (150 mEq NaHCO3 in 1 L D5W at 100-200 mL/hr) if hemodynamic compromise; target pH > 7.20
• Severe acidosis (pH < 7.10): May require RRT, especially if concurrent fluid overload or refractory hyperkalemia; sodium bicarbonate bolus (50-100 mEq) as temporizing measure
• The BICAR-ICU trial demonstrated that in AKI patients with severe metabolic acidosis (pH ≤ 7.20, bicarbonate ≤ 20 mmol/L, PaCO2 ≤ 45 mmHg), sodium bicarbonate targeting pH > 7.30 reduced the composite of death or at least one organ failure at day 7 compared to no bicarbonate (66% vs. 71%, p = 0.09 overall; significant benefit in the AKI subgroup with reduced 28-day mortality and reduced RRT requirement)⁷

2.3 Hyponatremia

Hyponatremia in AKI is most commonly dilutional (hypervolemic hyponatremia) due to impaired free water excretion.¹

Correction rate: Do not exceed 8-10 mEq/L correction in any 24-hour period to avoid osmotic demyelination syndrome. In patients on CRRT, monitor sodium closely as CRRT can cause rapid correction — adjust dialysate/replacement fluid sodium concentration if needed.

2.4 Hyperphosphatemia

Hyperphosphatemia results from decreased renal phosphate excretion in AKI and is particularly severe in tumor lysis syndrome and rhabdomyolysis.¹

• Target: Serum phosphorus < 5.5 mg/dL
• Treatment: Phosphate binders with meals (sevelamer 800-1600 mg TID, calcium acetate 1334 mg TID — avoid calcium-based binders if concurrent hypercalcemia); dietary phosphate restriction; RRT effectively removes phosphorus

2.5 Hypocalcemia

Hypocalcemia may occur in AKI due to hyperphosphatemia (calcium-phosphate precipitation), reduced 1,25-dihydroxyvitamin D production, and resistance to parathyroid hormone. Citrate anticoagulation during CRRT is an additional cause (see Part 4).¹

• Treat only if symptomatic (tetany, seizures, prolonged QT) or ionized calcium < 0.9 mmol/L
• Calcium gluconate 1-2 g IV over 10-20 minutes for symptomatic hypocalcemia
• Avoid aggressive calcium replacement if phosphorus is markedly elevated (risk of metastatic calcification)

3. Diuretic Therapy in AKI

3.1 Role of Diuretics

Diuretics — primarily loop diuretics (furosemide, bumetanide, torsemide) — are used in AKI to manage fluid overload, not to treat or prevent the underlying kidney injury. There is no evidence that diuretics improve outcomes, hasten renal recovery, or reduce the need for RRT. However, they are an essential tool for fluid management when residual kidney function is present.^{1 8}

Important distinctions:

• Diuretics do NOT improve AKI outcomes: Multiple studies and meta-analyses have shown that diuretics do not reduce mortality, need for RRT, or hasten renal recovery⁸
• Diuretics can manage complications of AKI: Effective fluid removal in patients with pulmonary edema, fluid overload, and volume-dependent hypertension
• Converting oliguric to non-oliguric AKI: While diuretics may increase urine output, this does not reflect improved kidney function — it merely makes fluid management easier

3.2 Loop Diuretic Dosing

Continuous infusion vs. intermittent bolus: The DOSE trial demonstrated no significant difference in outcomes between continuous infusion and intermittent bolus furosemide, but continuous infusion may provide more steady diuresis and be preferred in patients requiring large total daily doses.⁹

Combination diuretic therapy (“sequential nephron blockade”):

• Adding a thiazide diuretic (metolazone 2.5-10 mg PO or chlorothiazide 500 mg IV) 30 minutes before loop diuretic administration can synergistically enhance diuresis in diuretic-resistant patients
• Mechanism: Thiazides block sodium reabsorption in the distal convoluted tubule, preventing compensatory sodium reabsorption that limits loop diuretic efficacy
• Monitor closely for hypokalemia, hyponatremia, and excessive volume depletion

3.3 Furosemide Stress Test (FST)

The furosemide stress test is a standardized functional assessment of tubular integrity that predicts progression to severe AKI (Stage 3) and need for RRT. It is both a diagnostic and prognostic tool.¹⁰

Protocol

Prognostic Performance

Clinical Application: The FST can be used to (1) identify patients who may benefit from early nephrology consultation and RRT planning, (2) guide disposition decisions (patients with a positive FST may not need ICU-level monitoring for AKI), and (3) enrich future clinical trial populations for AKI intervention studies. The FST has an AUC of 0.87 for predicting subsequent need for RRT, which is superior to both clinical judgment and serum biomarkers at the time of early AKI.¹⁰

4. Drug Dosing Adjustments in AKI

4.1 General Principles

Drug dosing in AKI requires consideration of several factors:¹¹

• Volume of distribution (Vd): AKI patients often have expanded Vd due to fluid overload, edema, and capillary leak → loading doses should generally NOT be reduced
• Clearance: Renal drug clearance is reduced in proportion to GFR decline; non-renal clearance may also be affected (hepatic and GI dysfunction are common in critically ill patients with AKI)
• Protein binding: Uremia reduces protein binding of acidic drugs (phenytoin, warfarin) → increased free drug fraction → potential toxicity at “normal” total drug levels
• Active metabolites: Some drugs have renally excreted active metabolites that accumulate in AKI (e.g., morphine-6-glucuronide, normeperidine)
• RRT effects: CRRT and IHD remove drugs to varying degrees depending on molecular weight, protein binding, and volume of distribution (see Part 4)

4.2 Antimicrobial Dosing in AKI — Expanded Reference

4.3 Sedation and Analgesia in AKI

4.4 Anticoagulation in AKI

5. Nutritional Considerations in AKI

5.1 Energy Requirements

Critically ill patients with AKI have increased energy expenditure due to the catabolic state of critical illness, compounded by the additional metabolic burden of AKI (uremia, acidosis, inflammation).^{1 12}

5.2 Protein Requirements

Protein requirements vary significantly based on whether the patient is receiving RRT:^{1 12 13}

5.3 Micronutrient Considerations

6. Uremic Complications Requiring Urgent Intervention

6.1 Recognition of Uremia

Uremia represents the systemic toxicity caused by the accumulation of metabolic waste products normally excreted by the kidneys. Severe uremia is an absolute indication for RRT initiation.¹

Uremic Pericarditis — Special Warning: Uremic pericarditis is a hemorrhagic pericarditis that occurs in the setting of severe uremia (BUN typically > 100 mg/dL). It is an absolute indication for urgent RRT. Heparin must be avoided for RRT anticoagulation in these patients (risk of hemorrhagic tamponade); use regional citrate anticoagulation or no anticoagulation. If pericardial effusion with tamponade develops, emergent pericardiocentesis is required.

References